These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487 [TBL] [Abstract][Full Text] [Related]
5. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207 [TBL] [Abstract][Full Text] [Related]
6. Alternative and New Radiopharmaceutical Agents for Lung Cancer. Telo S; Calderoni L; Vichi S; Zagni F; Castellucci P; Fanti S Curr Radiopharm; 2020; 13(3):185-194. PubMed ID: 31868150 [TBL] [Abstract][Full Text] [Related]
7. Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Francis DL; Visvikis D; Costa DC; Arulampalam TH; Townsend C; Luthra SK; Taylor I; Ell PJ Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):988-94. PubMed ID: 12739071 [TBL] [Abstract][Full Text] [Related]
8. Assessment of biological parameters in head and neck cancer based on in vivo distribution of Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging. Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224 [TBL] [Abstract][Full Text] [Related]
10. Non-FDG PET in the practice of oncology. Caroli P; Nanni C; Rubello D; Alavi A; Fanti S Indian J Cancer; 2010; 47(2):120-5. PubMed ID: 20448372 [TBL] [Abstract][Full Text] [Related]
11. Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era. Garcia C; Flamen P Curr Opin Oncol; 2008 May; 20(3):275-9. PubMed ID: 18391626 [TBL] [Abstract][Full Text] [Related]
12. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074 [TBL] [Abstract][Full Text] [Related]
13. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411 [TBL] [Abstract][Full Text] [Related]
14. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
15. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Gulyás B; Halldin C Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239 [TBL] [Abstract][Full Text] [Related]
16. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
17. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model. Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer. Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Tanimoto K; Horiike A; Yanagitani N; Ohyanagi F; Nishio M Cancer Sci; 2015 Nov; 106(11):1554-60. PubMed ID: 26292100 [TBL] [Abstract][Full Text] [Related]
19. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552 [TBL] [Abstract][Full Text] [Related]
20. 3'-Deoxy-3'- Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]